

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

Correspondence to: Ann Marie Swart, MRC Clinical Trials Unit, London NW1 2DA, UK  
ams@ctu.mrc.ac.uk

	No brachytherapy (N=423)	Brachytherapy (N=477)
<b>Age (years)</b>		
Median (range)	66 (37-88)	64 (31-87)
<b>WHO/Eastern Cooperative Oncology Group performance status</b>		
0	270 (64%)	321 (67%)
1	138 (33%)	147 (31%)
2	14 (3%)	7 (2%)
3	1 (<1%)	2 (<1%)
<b>Surgery received</b>		
TAH/BSO	308 (73%)	327 (69%)
TAH/BSO/lymphadenectomy	115 (27%)	150 (32%)
<b>Histology</b>		
Endometrioid	365 (88%)	374 (79%)
Adenocarcinoma not otherwise specified	5 (1%)	27 (6%)
Clear cell	11 (3%)	11 (2%)
Papillary serous	10 (2%)	26 (5%)
Squamous	5 (1%)	5 (1%)
Mucinous	0	1 (<1%)
Mixed epithelial high grade	11 (3%)	24 (5%)
Mixed epithelial low grade	3 (1%)	1 (<1%)
Other epithelial, other mixed or no details	3 (1%)	6 (1%)
Mixed epithelial stromal (ineligible)	2 (1%)	0
Sarcoma (ineligible)	1 (<1%)	1 (<1%)
Unknown	7	1
<b>Differentiation or grade</b>		
Well (G1)	130 (31%)	96 (20%)
Moderate (G2)	160 (38%)	204 (43%)
Poor (G3)	98 (23%)	114 (24%)
Clear cell/serous papillary/mixed epithelial high grade	32 (8%)	61 (13%)
Not applicable (sarcoma and mixed epithelial stromal)	3	2
<b>Lymphovascular permeation</b>		
Yes	94 (25%)	106 (25%)
No	275 (75%)	317 (75%)
Not mentioned in the pathology report	43	51
Unknown	4	0

(Continues in next column)

	No brachytherapy (N=423)	Brachytherapy (N=477)
(Continued from previous column)		
<b>Positive peritoneal status</b>		
Yes	16 (4%)	18 (4%)
No	366 (96%)	452 (96%)
Not done	41	5
Unknown	0	2
<b>Nodes removed</b>		
No	271 (66%)	281 (65%)
Yes (lymphadenectomy or sampling)	141 (34%)	153 (35%)
Unknown	11	43
<b>Number of nodes removed</b>		
1-5	53	45
6-10	27	44
11-15	24	22
>15	32	37
Median (range) number of nodes removed	8 (1-40)	9 (1-39)
<b>Nodal involvement (if nodes removed)</b>		
No	132 (94%)	151 (99%)
Yes	9 (6%)	2 (1%)
<b>FIGO stage</b>		
IA (endometrium only)	12 (3%)	14 (3%)
IB (< inner half myometrium)	74 (18%)	80 (17%)
IC (outer half myometrium)	325 (77%)	350 (74%)
IIA (endocervical gland invasion)	7 (2%)	30 (6%)
IIB (cervical stromal invasion)	2 (1%)	1 (<1%)
III/IV (spread beyond uterus or cervix)	1 (<1%)	0
Unknown	2	2
<b>Risk group1</b>		
Intermediate risk	346 (83%)	345 (73%)
High risk	71 (17%)	128 (27%)
Unknown	6	4
TAH/BSO=total abdominal hysterectomy with bilateral salpingo-oophorectomy.		
<b>Webtable: Characteristics of patients who did and did not receive brachytherapy in ASTEC/EN.5</b>		